February 28, 2018 / 6:25 PM / 6 months ago

BUZZ-Intec Pharma shares up as Ladenburg initiates at "buy"

** Shares of Israel-based Intec Pharma were up >10 pct on Weds after Ladenburg Thalmann initiated coverage with a “buy” rating, set $13 PT

** Shares last up 5.9 pct at $6.25

** Lead analyst Michael Higgins calls Ph2 data on its Parkinson’s Disease treatment AP-CD/LD “impressive,” says drug has potential to unlock an estimated $5.6 bln U.S. market opportunity

** Sees NTEC’s Accordion Pill (a gastro-retentive delivery system) possibly improving cannabinoid therapies for pain treatment; Ph1 results show AP method can improve safety and efficacy

** In the first week of 2018, NTEC stock gained ~37 pct after co’s AP granted patent in Canada

** All 4 analysts covering NTEC rate co “buy” or stronger; median PT $14

** Even with today’s gain, stock has plummeted >61 pct over the last 12 months (Reporting by Stephen Culp)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below